- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05350371
Seguridad y tolerabilidad de la pirfenidona en la pancreatitis aguda
Evaluación de la pirfenidona como terapia en pacientes con pancreatitis aguda prevista de moderada a grave
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models. Following are the objectives of the proposed clinical trial:
Primary Objective:
- To evaluate the safety and tolerability of pirfenidone, compared to placebo, in patients predicted to have moderately severe or severe AP.
- To evaluate the efficacy of pirfenidone in reducing the laboratory markers of inflammation and improving patient reported outcome measures.
Secondary Objective:
- To evaluate the efficacy of pirfenidone in reducing the severity of acute pancreatitis, as measured by well-defined endpoints.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study is a Randomized Pilot clinical trial evaluating safety and tolerability of pirfenidone in patients with predicted moderately severe to severe acute pancreatitis. There are built in secondary end-points for efficacy. The patients with acute pancreatitis, who present within 48h of establishment of the diagnosis, will be screened for exclusion and inclusion criteria and consented for the clinical trial. Patients with be randomized into placebo or pirfenidone arm and followed daily in-person, while in hospital, and by telephone once discharged from the hospital (weekly for 4 weeks, then monthly for up to 6 months) for study end points.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- UAB
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Patients 18 - 85 years of age
-
Admitted to hospital for AP, defined by at least 2 of the following 3:
- amylase or lipase values, or both, that are greater than 3 times the upper limit of normal values
- characteristic cross-sectional imaging
- typical upper abdominal pain- acute onset of a persistent, severe, epigastric pain often radiating to the back
-
Patients identified, approached, and consented to administer study medication or placebo within 48 hours of diagnosis of AP.
-
Predicted to have MSAP or SAP by presence of one or more of the following criteria
- APACHE II ≥ 8
- Modified Glasgow or Imrie score ≥ 3
- CRP > 150 mg/dL
- PASS score > 140 at or within 48 hrs. of admission
- CT or MRI imaging suggesting pancreatic and/or peri-pancreatic necrosis
Exclusion Criteria:
- Age < 18 or > 85 years
- Body weight > 200 kg
- Presentation to the medical attention > 48 h after diagnosis of AP
- Inability to recruit, randomize and start the allocated treatment within 48h of start of pain
- Ongoing AP or diagnosis of AP in previous 30 days
- Chronic pancreatitis
- Known hypersensitivity to pirfenidone
- AST/ALT ≥ 2 times the upper normal limit.
- Alkaline phosphatase ≥ 2 times the upper normal limit
- Bilirubin higher than upper normal limit
- Moderate to severe heart failure and/or coronary heart disease (New York Heart Association (NYHA) Functional Class III/IV)
- On home oxygen or home mechanical ventilation
- Advanced liver disease
- Paralytic ileus or significant nausea and vomiting
- Chronic Diarrhea
- Immunosuppressive disorder or on immunosuppressive medications
- Active or advanced malignancy
- Known cancer that is end-stage with ongoing palliative care or for which palliative care is appropriate
- Known established infection prior to the onset of acute pancreatitis
- Known history of infective hepatitis
- Known live vaccines or therapeutic infectious agents within one month of admission
- Known pregnancy or lactation at the time of admission
- Ongoing photosensitivity and rash
- Women of childbearing potential who are not on oral or injectable contraceptives or IUDs and do not consent to practice abstinence for period of 4 weeks.
- Known to be currently participating in a trial testing any investigational medicinal product or participation in a clinical study involving a medicinal product in the last three months
- Alcohol or substance abuse in the past 2 years
- Family or personal history of long QT syndrome ( > 500 msec)
- Medications like fluvoxamine or sildanefil
- Significant photosensitivity or new rash
- Renal disease with GFR < 30
- Any condition other than above that, in the opinion of the investigator, is likely to result in the death of the patient within the next 2 years
- Any condition that, in the opinion of the investigator, might be significantly exacerbated by the known side effects associated with the administration of pirfenidone
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Placebo
|
The placebo tablets will be an exact replica of the pirfenidone tablet. |
|
Experimental: Tratamiento con pirfenidona
|
Patients in the pirfenidone treatment arm will be given pirfenidone 267mg tablet, tid for 1 day followed by dose escalation to two 267 mg tablet tid for 6 days. Thus, the treatment will be for total of 7 days or till patients develop an adverse event that requires their participation in the study to be stopped. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Development of Anticipated or Un-anticipated Adverse Events (Class 3 or 4)
Periodo de tiempo: 6 months
|
Development of anticipated or un-anticipated adverse events (class 3 or 4) |
6 months
|
|
Percentage of Patients Starting and Completion of the Planned Drug Treatment
Periodo de tiempo: 7 days
|
percentage of patients starting and completion of the planned drug treatment |
7 days
|
|
Changes in C-reactive Protein (CRP), TNF-α, Interleukin (IL)-6, IL-8 and IL-10 Levels
Periodo de tiempo: 7 days
|
Compared to base line |
7 days
|
|
Percentage of Patients Having Decrease in PAN-PROMISE Score by at Least 10 Points at 72h After Initiation of the Drug
Periodo de tiempo: 3 days
|
Measurement of PAN-PROMISE score |
3 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cumulative PAN-PROMISE Score
Periodo de tiempo: 7 days
|
total of the PAN-PROMISE over 7 days |
7 days
|
|
Cumulative PASS Score
Periodo de tiempo: duration of admission
|
total of PASS score during admission |
duration of admission
|
|
PASS Score at the Time of Discharge
Periodo de tiempo: duration of admission
|
PASS score measurement |
duration of admission
|
|
Composition Outcome
Periodo de tiempo: 6 months
|
total of development of new or worsening pancreatic or peri-pancreatic necrosis, death or major infection |
6 months
|
|
Readmission and/or ER Visits
Periodo de tiempo: within 30 days and within 6 months
|
within 30 days and within 6 months
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Palathingal Bava E, George J, Tarique M, Iyer S, Sahay P, Gomez Aguilar B, Edwards DB, Giri B, Sethi V, Jain T, Sharma P, Vaish U, C Jacob HK, Ferrantella A, Maynard CL, Saluja AK, Dawra RK, Dudeja V. Pirfenidone increases IL-10 and improves acute pancreatitis in multiple clinically relevant murine models. JCI Insight. 2022 Jan 25;7(2):e141108. doi: 10.1172/jci.insight.141108.
- Bava EP, Jain T, Al-Obaidi M, Evans Z, Doto D, Vege SS, Dudeja V. Safety, tolerability and therapeutic efficacy of anti-inflammatory drug pirfenidone in acute pancreatitis patients: Protocol for a randomized pilot clinical trial. Pancreatology. 2025 Mar;25(2):214-220. doi: 10.1016/j.pan.2025.01.004. Epub 2025 Jan 13.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB-300008875
- W81XMH2110665 (Otro número de subvención/financiamiento: U.S. Department of Defense)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .